ATNF Insider Trading Activity and SEC Form 4 Filings
ATNF insider trading summary
No open-market insider purchases or sales of 180 Life Sciences Corp. (ATNF) have been reported on SEC Form 4 in the past 12 months.
Latest ATNF insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 15, 2023 | James N. Woody | Chief Executive Officer | Buy | $5K (25,000 @ $0.19) |
| Dec 15, 2023 | Marc Feldmann | Director | Sell | $5K (25,000 @ $0.19) |
| Jun 1, 2023 | Lawrence Steinman | Director | Buy | $22K (18,000 @ $1.23) |
| May 31, 2023 | Donald A. McGovern Jr. | Director | Buy | $11K (10,000 @ $1.15) |
| May 19, 2023 | Donald A. McGovern Jr. | Director | Buy | $6K (5,000 @ $1.16) |
| May 18, 2023 | Ozan Pamir | CFO | Buy | $5K (5,162.077 @ $1.01) |
| May 18, 2023 | Pamela G Marrone | Director | Buy | $8K (7,082.019 @ $1.06) |
| May 18, 2023 | Donald A. McGovern Jr. | Director | Buy | $11K (10,000 @ $1.05) |
| May 18, 2023 | James N. Woody | Chief Executive Officer | Buy | $41K (40,000 @ $1.03) |
| Dec 16, 2021 | Quan Anh Vu | COO / Chief Business Officer | Buy | $32K (8,000 @ $3.98) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.